**Ongoing IPO issuance in October 2026 reflects resilient equity capital markets despite selective investor demand and macroeconomic pressures.** Multiple traditional and SPAC offerings have priced recently or are scheduled imminently, including biotech-focused deals such as Frazier Life Sciences Acquisition II and clinical-stage names like Iambic Therapeutics and City Therapeutics, alongside broader activity in healthcare and technology. Year-to-date U.S. traditional IPO proceeds already exceed prior-year totals, supported by a deep pipeline and improving aftermarket performance in select sectors, even as concerns over AI spending, rate volatility, and inflation influence valuations. With several filings effective and additional launches expected before year-end, trader consensus prices in a high implied probability of further IPO activity through the remainder of 2026. Key near-term catalysts include upcoming earnings, Fed communications, and any acceleration in mega-cap filings.